Vivos Adds Commercial Expertise to its Veterinary Medicine Advisory Board
March 20 2018 - 9:30AM
Richland, WA, March 20, 2018 (GLOBE NEWSWIRE) --
Vivos Inc (OTC: RDGL) announced today that it added a new
member on the Veterinary Medicine Advisory
Board.
Tariq Shah BSc. DipMS is the founder and director of Oncologize,
a consulting company that provides a direct link between the
biotech companies and veterinary oncologists within the United
States
Tariq Shah has been working within Animal Health for 25 years. A
graduate in Marine Biology from the University of Liverpool, United
Kingdom, he has held managerial positions for both veterinary
pharmaceutical companies and veterinary diagnostic laboratories.
Since he came to the US in 2008, he has worked with veterinary
oncologists across America, conducting research and commercializing
diagnostic technology.
He holds an adjunct faculty position at the University of
Missouri College of Veterinary Medicine, which is our key canine
testing center. In 2017 he established Oncologize, a pioneering
company designed to support and assist organizations in their
development and commercialization of oncology products.
Tariq Shan said he is extremely happy to be supporting
IsoPetTM in this exciting venture and to work with Dr.
Alice Villalobus, the Chair of the Board. Dr. Mike Korenko stated
“Tariq’s experience is very relevant to our thrust to commercialize
IsoPetTM by partnering with the private clinics
consortiums.”
About Vivos Inc. (OTC: RDGL)
Currently, the Company is engaged in the development of a
Yttrium-90 based brachytherapy device, for the treatment of tumors
in animals and people. Brachytherapy uses radiation to destroy
cancerous tumors by placing a radioactive isotope inside the
treatment area.
IsoPetTM for treating animals is the same product as
RadioGelTM for treating humans. The Food and Drug
Administration advised using different names in order to avoid
confusion and cross-use.
IsoPetTM is a hydrogel liquid containing tiny
Yttrium-90 phosphate particles to be injected into a
tumor.
This hydrogel is a liquid at temperatures below body temperature
but begins to gel, harden, upon injection as the temperature
increases to normal body temperature, thereby locking the particles
in place. The particles emit a very high concentrated and contained
beta irradiation to kill the tumor. The beta radiation has a short
penetration distance so there is minimal collateral damage to
healthy tissues outside of the injected area.
IsoPetTM also has a short half-life – delivering more
than 90% of its therapeutic radiation within 10 days. This
compares favorably to other available treatment options requiring
up to 6 weeks or more to deliver a full course of radiation
therapy. This is an outpatient treatment much safer to the
personnel treating the patient than competing brands and the
patient can go home immediately with no risk to family members.
The IsoPetTM Solutions division of RDGL is using
university veterinary hospitals to demonstrate the safety and
therapeutic effectiveness for different animal cancers. The testing
on feline sarcoma at the Washington State University is completed
and the testing on canine soft tissue sarcomas at University of
Missouri will begin in the near future.
The Company recently obtained classification clarification from
the FDA that they are a device for therapy on skin cancer in
animals and they approved our label. No other regulatory approval
is required for skin cancer, which is the largest market
sector. RDGL is positioning itself so that after this
demonstration phase, the Company can begin to generate revenues
through the sale of IsoPetTM to private animal clinic
consortiums.
The Company is also engaging the FDA for permission to use
RadioGelTM for the treatment of advanced basal and
squamous cell skin cancers in humans.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
You can identify these statements by the use of the words "may,"
"will," "should," "plans," "expects," "anticipates," "continue,"
"estimates," "projects," "intends," and similar expressions.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those projected or
anticipated. These risks and uncertainties include, but are not
limited to, the Company's ability to successfully execute its
expanded business strategy, including by entering into definitive
agreements with suppliers, commercial partners and customers;
general economic and business conditions, effects of continued
geopolitical unrest and regional conflicts, competition, changes in
technology and methods of marketing, delays in completing various
engineering and manufacturing programs, changes in customer order
patterns, changes in product mix, continued success in technical
advances and delivering technological innovations, shortages in
components, production delays due to performance quality issues
with outsourced components, regulatory requirements and the ability
to meet them, government agency rules and changes, and various
other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com
509-736-4000
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Sep 2023 to Sep 2024